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GeneticvariationsinDNArepairgenesarethoughttomodulateDNArepaircapacityandaresuggestedtoberelatedtolungcancer
risk. We conducted a meta-analysis of epidemiologic studies on the association between genetic polymorphisms in both base
excision repair and nucleotide excision repair pathways, and lung cancer. We found xeroderma pigmentosum complementation
group A (XPA) G23A (odds ratio (OR) = 0.76, 95% conﬁdence interval (CI) = 0.61–0.94), 8-oxoguanine DNA glycosylase 1
(OGG1) Ser326Cys (OR = 1.22, 95%CI = 1.02–1.45), and excision repair cross-complementing group 2 (ERCC2) Lys751Gln
(OR = 1.27, 95%CI = 1.10–1.46) polymorphisms were associated with lung cancer risk. Considering the data available, it can be
conjecturedthatifthereisanyriskassociationbetweenasingleSNPandlungcancer,theriskﬂuctuationwillprobablybeminimal.
Advances in the identiﬁcation of new polymorphisms and in high-throughput genotyping techniques will facilitate the analysis of
multiple genes in multiple DNA repair pathways. Therefore, it is likely that the deﬁning feature of future epidemiologic studies will
be the simultaneous analysis of large samples of cases and controls.
1.Introduction
Sporadic cancer is a multifactorial disease that results from
complex interactions between many genetic and environ-
mental factors [1]. This means that there will not be a single
gene or single environmental factor that has large eﬀects
on cancer susceptibility. Environmental factors (e.g., tobacco
smoke, dietary factors, infectious agents, and radiation) add
to the carcinogenic load to which humans are exposed,
but exact numbers for added risk are generally less well
established.
Cigarettesmokecontainsseveralthousandchemicalsthat
are known to chemically modify DNA [2] and lead to the
formation of mutations [3]. Most of these compounds are
procarcinogens that must be activated by Phase I enzymes,
such as cytochrome P450s. All activated carcinogens can
bind to DNA and form DNA adducts that are capable of
inducingmutationsandinitiatingcarcinogenesis.Thecapac-
ity to repair DNA damage induced by activated carcinogens
appears to be one of the host factors that may inﬂuence lung
cancer risk. A critical cellular response that counteracts the
carcinogenic eﬀects of DNA damage is DNA repair.
Several studies have investigated whether reduced DNA
repair capacity (DRC) is associated with an increased risk
of cancer [4]. The reduced DRC of benzo(a)pyrene-7,8-
diol-9,10-epoxide (an active form of benzo(a)pyrene)-DNA
adducts is associated with an increased risk of lung cancer
(2.1-fold, 95% conﬁdence interval (CI) = 1.5–3.0) [5]. The
reduced DRC has been shown to be associated with a 5.7-
fold (95% CI = 2.1–15.7) increased risk of developing lung
cancer[6].Likewise,thereducedDRCofbleomycin-induced
damage was found to be associated with an increased risk of
lung cancer [7]. These studies suggested that a low DRC of
various DNA repair mechanisms predisposes individuals to2 Journal of Nucleic Acids
lung cancer, and this realization prompted us to search for
deﬁned DNA repair activities that may be risk factors for
lung cancer. Polymorphisms in DNA repair genes may be
associated with diﬀerences in the DRC of DNA damage and
may inﬂuence an individual’s risk of lung cancer, because the
variant genotype in those polymorphisms might destroy or
alter repair function.
At least four pathways of DNA repair operate on speciﬁc
types of damaged DNA. Base excision repair (BER) operates
on small lesions, while the nucleotide excision repair (NER)
pathway repairs bulk lesions. Mismatch repair corrects
replication errors. Double-strand DNA break repair (DSBR)
actually consists of two pathways, homologous recom-
bination (HR) and nonhomologous end-joining (NHEJ).
The NHEJ repair pathway involves direct ligation of the
two double strand break ends, while HR is a process by
which double-strand DNA breaks are repaired through the
alignment of homologous sequences of DNA. The following
sections review the literature on DNA repair genes in more
detail, speciﬁcally those involved in the NER and BER
pathways.
It is believed that the predominant pathway used for
removal of oxidized and many of the alkylated bases is BER.
The process of BER is initiated by DNA glycosylases [e.g.,
8-oxoguanine DNA glycosylase 1 (OGG1), endonuclease
III homolog 1, thymine glycol-DNA-glycosylase], which are
often promiscuous as far as their substrate speciﬁcity is
concerned. The BER pathway can proceed through two
diﬀerent subpathways: short-patch and long-patch BER.
These pathways are diﬀerentiated by the enzymes involved
and the number of nucleotides removed. Short-patch BER
replaces a single nucleotide by polymerase β and the newly
synthesized DNA sealed by DNA ligase III/X-ray cross-
complementing group 1 (XRCC1) heterodimer [8]. Long-
patch BER inserts 2–13 nucleotides by concordant action
of polymerase δ, proliferating cell nuclear antigen, ﬂap
endonuclease 1, and ligase I.
NER is a versatile DNA repair system that removes a
wide range of DNA lesions including UV-induced lesions.
There are two subpathways in NER. One is transcription-
coupled DNA repair (TCR), which preferentially removes
DNA damage that blocks ongoing transcription in the
transcribed DNA strand of active genes. The other is global
genomerepair(GGR),whichremoveslesionsthroughoutthe
genome, including those from the nontranscribed strand in
the active gene [9]. Three rare, autosomal recessive inherited
human disorders are associated with impaired NER activity:
XP, CS, and trichothiodystrophy (TTD) [10]. XP has been
studied most extensively. Seven diﬀerent DNA NER genes,
which correct seven distinct genetic XP complementation
groups (XPA, XPB (excision repair cross-complementing
group 3, ERCC3), XPC, XPD (ERCC2), XPE, XPF (ERCC4)
and XPG (ERCC5, this gene causes CS)) and XPV have been
identiﬁed[10].XPA,ERCC3/XPB,ERCC2/XPD,ERCC4/XPF
and ERCC5/XPG have a defect in TCR and GGR, while XPC
and XPE have a defect in GGR only. ERCC6 and ERCC8 are
also known as CS type B (CSB) and CSA,r e s p e c t i v e l y .
The aim of this article is to review and evaluate
associations between genes in the BER and NER pathways,
focusing on genetic polymorphisms in O G G 1 ,X R C C 1 ,X P A ,
and ERCC2 genes, which have been reported a suﬃcient
number of studies to conduct a meta-analysis. The details
of the OGG1, XRCC1, XPA,a n dERCC2 genes are given in
Table 1
2.MaterialsandMethods
2.1. Identiﬁcation and Eligibility of Relevant Studies. We con-
ducted MEDLINE, Current Contents, and Web of Science
searches using “OGG1”, “XRCC1”, “XPA”, “ERCC2/XPD”,
“lungcancer”,and“polymorphism”askeywordstosearchfor
papers published (from January 1, 1966 through December
31, 2009). Additional articles were identiﬁed through the
references cited in the ﬁrst series of articles selected. Articles
included in the meta-analysis were in English language,
with human subjects. Case-control studies were eligible
if they had determined the distribution of the relevant
genotypes in lung cancer cases and in concurrent controls
using a molecular method for genotyping. For overlap-
ping studies, only the ﬁrst published one was selected.
Using the MEDLINE database, we identiﬁed 18 genetic
epidemiological studies that provided information on lung
cancer occurrence associated with the OGG1 Ser326Cys
polymorphism. Also, we identiﬁed 22 studies of the XRCC1
Arg399Gln polymorphism, 12 studies of XRCC1 Arg194Trp
polymorphism, and 10 studies of the XRCC1 Arg280His
polymorphism. As for NER polymorphisms, we identiﬁed
6 studies for the XPA G23A polymorphism, 16 studies
for the Asp312Asn polymorphism, and 19 studies for the
Lys751Gln polymorphism. No additional articles through
Current Contents or Web of Science have been identiﬁed.
2.2. Data Extraction and Assessment of Study Quality. For
each study, characteristics such as authors, year of publica-
tion, ethnic group of the study population, source of control
population, number of genotyped cases and controls, crude
odds ratio (OR), and the method for quality control of
genotyping were noted. For studies including subjects of
diﬀerent ethnic groups, data were extracted separately for
each ethnic group whenever possible.
Methods for deﬁning study quality in genetic studies
are more clearly delineated than those for observational
studies. We combined only studies with allelic frequencies
being in Hardy-Weinberg equilibrium (HWE) (Pearson χ2
test, P ≥ .05) because departure from HWE can imply the
presence of genotyping error, possible ethnic admixture in
the population, or selection bias (lack of representativeness
of the general population). We assessed the homogeneity of
the study population (Caucasian or Asian).
2.3. Meta-Analysis. Data were combined using both a ﬁxed
eﬀects (the inverse variance-weighted method) and a ran-
dom eﬀects (DerSimonian and Laird method) models [11].
The Cochran Q statistics test is used for the assessment
of heterogeneity. The ﬁxed eﬀects model is used when
the eﬀects are assumed to be homogenous, while the
random eﬀects model is used when they are heterogenous.Journal of Nucleic Acids 3
Table 1: The details of the OGG1, XRCC1, XPA,a n dERCC/2XPD genes.
Gene symbol Gene name Gene
location Polymorphism DNA repair capacity
OGG1 8-oxoguanine DNA
glycosylase 3p26.2 Ser326Cys (rs1052133) The Cys/Cys genotype may be associated with a
lower DNA repair capacity
XRCC1
X-ray repair
complementing defective
repair in Chinese hamster
cells 1
19q13.2
Arg194Trp (rs1799782),
Arg280His (rs25489),
Arg399Gln (rs25487)
Although the Arg399Gln, Arg194Trp, and
Arg280His polymorphisms have been suggested to
be functional, there is no direct evidence on its
functional consequences
XPA Xeroderma pigmentosum,
complementation group A 9q22.3 G23A (rs 1800975) The G allele may be associated with a higher DNA
repair capacity
ERCC2/XPD
Excision repair
cross-complementing
group 2/ Xeroderma
pigmentosum,
complementation group D
19q13.3 Asp312Asn (rs1799793),
Lys751Gln (rs13181)
The 312Asn and 751Gln alleles are reported to be
associated with lower DNA repair capacity
In the absence of between-study heterogeneity, the two
methods provide identical results. The presence of het-
erogeneity can result from diﬀerences in the selection of
controls, age distribution, prevalence of lifestyle factors,
histological type of lung cancer, stage of lung cancer, and
so on. The random eﬀects model incorporates an estimate
of the between-study variance and tends to provide wider
CIs when the results of the constituent studies diﬀer among
themselves. As the random eﬀects model is more appropriate
when heterogeneity is present [11], the summary OR and
prevalence were essentially based on the random eﬀects
model. The meta-analyses were performed on crude ORs,
since the adjusted ORs were not comparable because of the
inclusionofdiﬀerentcovariatesinthemultivariateregression
models. Using individuals with the homozygous common
genotype as the reference group, we calculated ORs for
individualswiththeheterozygousgenotypeandhomozygous
rare genotype separately whenever possible (information
available in at least two studies). In some cases, we com-
bined the heterozygous genotype with the homozygous rare
genotype due to a low prevalence of the rare allele in several
polymorphisms. The Q statistic was considered signiﬁcant
for P<. 10 [12, 13]. Publication bias is always a concern
in meta-analysis. The presence of publication bias indicates
that nonsigniﬁcant or negative ﬁndings remain unpublished.
To test for publication bias, both Begg’s [14]a n dE g g e r ’ s[ 15]
tests are commonly used to assess whether smaller studies
reported greater associations than larger studies. Publication
bias is considered signiﬁcant for P<. 10. For each genetic
comparison, subgroup analysis was stratiﬁed by the ethnicity
and, if possible, histological type of lung cancer. All of the
calculationswereperformedusingSTATAVersion10.1(Stata
Corporation, College Station, TX) software.
3. Results
3.1. OGG1 Ser326Cys Polymorphism. Table 2 shows the
individual ORs from each study and summary ORs of the
OGG1 Ser326Cys polymorphism [16–33]. Two studies [24,
26] were excluded from the meta-analysis because genotype
distributionincontrolpopulationsigniﬁcantlydeviatesfrom
HWE. Combining data from all 17 populations on the basis
of 6,181 cases and 7,331 controls, the summary ORs were
1.04(95%CI =0.94–1.23)forSer/Cyscarriersand1.22(95%
CI = 1.02–1.45) for Cys/Cys carriers. The Cys/Cys genotype
was signiﬁcantly associated with lung cancer risk in all
populations combined. The summary ORs for the Cys/Cys
genotype in Caucasians (mostly composed of Caucasians)
andAsianswere1.24(95%CI =0.84–1.83)and1.24(95%CI
= 1.00–1.55, P = .052), respectively. There was a marginally
signiﬁcant association between lung cancer risk and the
OGG1 Ser326Cys polymorphism among Asians. Publication
bias was absent in all analyses. Heterogeneity was present in
the analyses of all studies combined and Caucasian studies
combined.
A further analysis on histological type was performed
to assess whether the impact of the OGG1 Ser326Cys
polymorphism between adenocarcinoma and squamous cell
carcinoma cases (the two histological types present most
often in the data set) was similar or not. Among the
seven case-control studies (2,052 lung cancer cases and
3,032 controls), the summary OR for the Cys/Cys genotype
in adenocarcinoma was 1.38 (95% CI = 1.12–1.75) (data
not shown). Among both Caucasians (612 cases and 2,618
controls) [17, 22, 25] and Asians (1,440 cases and 864
controls) [16, 19, 28, 32], subjects with the Cys/Cys genotype
were at increased risk of adenocarcinoma. Summary ORs for
Caucasians and Asians were 1.90 (95% CI = 0.99–3.63, P =
.054) ad 1.30 (95% CI=1.00–1.29, P = .049), respectively
(data not shown). It was found that increased risk associated
with the Cys/Cys genotype wasnot evident forsquamouscell
lungcancerriskamongCaucasians[17,22,25].Theavailable
data on squamous cell carcinoma are insuﬃcient for Asians.
3.2. XRCC1 Polymorphism. Table 3 shows that summary
ORs of the XRCC1 Arg399Gln polymorphism on the basis
of 8,684 cases and 10,913 controls [23, 25–27, 30, 33–49].
The summary OR for the 339Gln/Gln genotype among 24
diﬀerent ethnic populations was 1.00 (95% CI = 0.86–1.17).
The Cochran Q test for heterogeneity showed a statistical4 Journal of Nucleic Acids
Table 2: Genetic polymorphisms in the BER pathway and lung cancer risk: OGG1 Ser326Cys polymorphism.
Author, published year
(reference no.) Ethnicity No. of
Cases/Controls
Source of
controls
OR (95% CI)∗ Quality control of
genotyping
Ser/Cys Cys/Cys
Sugimura et al., 1999 [16] Asian 241/197 Hospital 0.80
(0.52–1.21)
1.13
(0.63–2.02) Sequencing
Wikman et al., 2000 [17] Caucasian 105/105 Hospital 0.66
(0.37–1.17)
2.20
(0.41–11.8) Sequencing
Ito et al., 2002 [18] Asian 138/240 Hospital 1.02
(0.63–1.67)
0.85
(0.46–1.56) None
Sunaga et al., 2002 [19] Asian 198/152 Hospital 1.49
(0.91–2.43)
0.98
(0.54–1.77) None
Le Marchand et al., 2002 [20] Admixed
population 298/405 Population 0.90
(0.65–1.26)
1.76
(1.15–2.71) Sequencing
Lan et al., 2004 [21] Asian 118/109 Population 1.96
(1.10– 3.48)
1.84
(0.83–4.06) None
Park et al., 2004 [22]
Mostly
composed of
Caucasians
179/350 Screening 1.89
(1.27–2.80)
4.10
(1.65–10.2) Sequencing
Vogel et al., 2004 [23] Caucasian 256/269 Population 1.09
(0.75– 1.60)
0.78
(0.35–1.72)
Replication
(random samples)
Liang et al., 2005 [24]‡ Asian 227/227 Hospital 0.94
(0.63–1.41)
0.98
(0.33–2.87) Sequencing
Hung et al., 2005 [25]
Mostly
composed of
Caucasians
2,155/2,163 Hospital 0.90
(0.79–1.03)
1.15
(0.84–1.57)
Replication
(random samples)
Zienolddiny et al., 2006 [26]‡ Caucasian 326/386 Population 0.91
(0.64–1.29)
0.63
(0.40–0.97)
Replication (all
samples)
Matullo et al., 2006 [27] Caucasian 116/1094 Population 1.26
(0.83– 1.91)
0.82
(0.21–2.33)
Replication
(random samples)
Kohno et al., 2006 [28] Asian 1097/394 Hospital 1.24
(0.94–1.63)
1.43
(1.02–2.01) None
Sørensen et al., 2006 [29] Caucasian 431/796 Population 1.04
(0.80–1.35)
1.18
(0.63–2.21)
Replication
(random samples)
De Ruyck et al., 2007 [30] Caucasian 110/110 Hospital 0.58
(0.33–1.02)
0.61
(0.13–2.82) None
Karahlil et al., 2008 [31] Turkish 165/250 Hospital 0.82
(0.54–1.24)
0.65
(0.32–1.29) None
Miyaishi et al., 2009 [32] Asian 108/121 Hospital 1.47
(0.79–2.73)
1.34
(0.65–2.77) None
Chang et al., 2009 [33] Latino 112/296 Population 0.91
(0.56–1.47)
1.05
(0.45–2.32)
Replication
(random samples)
Chang et al., 2009 [33] African-
American 254/280 Population 1.32
(0.89–1.98)
0.89
(0.25–3.00)
Replication
(random samples)
Summary∗∗ No. of
populations
Cochran Q test for
heterogeneity
Ser/Cys Cys/Cys
All 17 6,181/7,331 1.04
(0.94–1.23)
1.22
(1.02–1.45) 0.004 0.220
Caucasian (mostly composed
of Caucasians) 7 3,352/4,887 1.02
(0.81–1.29)
1.24
(0.84–1.83) 0.004 0.133
Asian 6 1,900/1,213 1.23
(0.97–1.55)
1.24
(1.00–
1.55)†
0.159 0.572
∗Crude odds ratio and 95% conﬁdence interval.
∗∗Based on random eﬀects model.
†P = .052.
‡Excluded from the meta-analysis because genotype distribution of control population was not in Hardy-Weinberg equilibrium. NA, not available.Journal of Nucleic Acids 5
Table 3: Genetic polymorphisms in the BER pathway and lung cancer risk: XRCC1 Arg399Gln polymorphism.
Author, published year
(reference no.) Ethnicity No. of
Cases/Controls
Source of
controls
OR (95% CI)∗ Quality control of
genotyping
Arg/Gln Gln/Gln
Ratnasinghe et al., 2001 [34] Asian 107/208 Population 1.00
(0.60–1.60)
1.40
(0.50–1.70)
Replication
(random sample)
David-Beabes and London ,
2001 [35]
African-
American 154/243 Population 1.03
(0.66–1.60)
0.52
(0.14–1.97)
Replication
(random sample)
David-Beabes and London ,
2001 [35] Caucasian 180/461 Population 0.75
(0.52–1.08)
0.63
(0.34–1.14)
Replication
(random sample)
Divine et al., 2001 [36] Caucasian 172/143 Hospital 0.76
(0.47–1.22)
1.64
(0.80–3.36) None
Chen et al., 2002 [37] Asian 109/109 Population 1.02
(0.57–1.80)
0.67
(0.20–2.26) None
Park et al., 2002 [38] Asian 192/135 Hospital
visitors
1.27
(0.81–2.04)
2.30
(0.87–6.09) Sequencing
Misra et al., 2003 [39] Caucasian 315/313 Population 1.10
(0.78–1.54)
0.84
(0.45–1.58)
Replication
(random sample)
Zhou et al., 2003 [40] Caucasian 1,091/1,240 Hospital
visitors
1.00
(0.80–1.20)
1.30
(1.00–1.70)
Replication
(random sample)
Ito et al., 2004 [41] Asian 178/449 Hospital 1.01
(0.70–1.45)
1.39
(0.70–2.76) None
Popanda et al., 2004 [42] Caucasian 463/460 Hospital 0.89
(0.67–1.17)
0.87
(0.58–1.29)
Replication
(random sample)
Harms et al., 2004 [43] Caucasian 110/119 Hospital 0.73
(0.44–1.25)
1.07
(0.39–2.96)
Replication (all
samples)
Zhang et al., 2005 [44] Asian 1,000/1,000 Hospital 0.95
(0.79–1.14)
1.14
(0.84–1.55)
Replication (all
samples)
Hung et al., 2005 [25]
Mostly
composed of
Caucasians
2,049/2,015 Hospital 1.12
(0.98–1.28)
1.01
(0.83–1.23)
Replication
(random sample)
Vogel et al., 2004 [23] Caucasian 256/269 Population 0.79
(0.54–1.17)
0.81
(0.46–1.41)
Replication
(random sample)
Schneider et al., 2005 [45] Caucasian 446/622 Hospital 0.94
(0.72–1.23)
0.83
(0.54–1.26) None
Shen et al., 2005 [46] Asian 116/109 Population 0.59
(0.33–1.05)
0.75
(0.13–4.23) None
Zienolddiny et al., 2006 [26] Caucasian 331/391 Population 1.08
(0.78–1.49)
0.67
(0.39–1.14)
Replication (all
samples)
Matullo et al., 2006 [27] Caucasian 116/1,094 Population 1.14
(0.75–1.73)
0.52
(0.19-1.19)
Replication
(random sample)
Yin et al., 2007 [47] Asian 205/193 Hospital 1.20
(0.77–1.85)
0.21
(0.05–1.00) None
L´ opez-Cima et al., 2007 [48] Caucasian 516/533 Hospital 0.91
(0.70–1.20)
0.89
(0.61–1.31) Sequencing
Pachouri et al., 2007 [49] Asian 103/122 Population 0.36
(0.20–0.64)
0.47
(0.20–1.09) None
De Ruyck et al., 2007 [30] Caucasian 109/109 Hospital 1.28
(0.69–2.28)
1.68
(0.67–4.23) None
Chang et al., 2009 [33] Latino 112/296 Population 1.30
(0.73–2.30)
3.03
(1.11–7.83)
Replication
(random sample)
Chang et al., 2009 [33] African-
American 254/280 Population 1.02
(0.62–1.65)
1.19
(0.24–5.13)
Replication
(random sample)
Summary∗∗ No. of
populations
Cochran Q test for
heterogeneity
Arg/Gln Gln/Gln
All 24 8,684/10,913 0.97
(0.89–1.05)
1.00
(0.86–1.17) 0.153 0.004
Caucasian (mostly composed
of Caucasians) 13 6,154/7,769 1.00
(0.92–1.08)
0.95
(0.83–1.10) 0.433 0.218
Asian 8 2,010/2,325 0.90
(0.72–1.13)
1.08
(0.78–1.49) 0.024 0.030
∗Crude odds ratio and 95% conﬁdence interval..
∗∗Based on random eﬀects model.6 Journal of Nucleic Acids
Table 4: Genetic polymorphisms in the BER pathway and lung cancer risk: XRCC1 Arg194Trp polymorphism.
Author, published year
(reference no.) Ethnicity No. of
Cases/control
Source of
controls
OR (95% CI)∗ Quality control of
genotyping
Arg/Trp Trp/Trp
Ratnasinghe et al., 2001 [34] Asian 108/216 Population 0.70
(0.40–1.20)
0.70
(0.30–1.60)
Replication
(random sample)
David-Beabes and London ,
2001 [35]
African-
American 154/234 Population 0.40
(0.19–0.83)
1.44
(0.20–
10.37)
Replication
(random sample)
David-Beabes and London ,
2001 [35] Caucasian 180/461 Population 1.05
(0.62–1.78) — Replication
(random sample)
Chen et al., 2002 [37] Asian 109/109 Population 1.31
(0.73–2.32)
2.61
(0.85– 8.04) None
Hung et al., 2005 [25]
Mostly
composed of
Caucasians
2,147/2,132 Hospital 0.86
(0.72–1.03)
0.81
(0.35–1.88)
Replication
(random sample)
Schneider et al., 2005 [45] Caucasian 446/622 Hospital 0.99
(0.67–1.46)
1.86
(0.31–12.8) None
Shen et al., 2005 [46] Asian 118/112 Population 1.01
(0.56–1.83)
1.48
(0.51–4.45) None
Zienolddiny et al., 2006 [26] Caucasian 336/405 Population 0.88
(0.50–1.55)
0.60
(0.01–11.5)
Replication (all
samples)
Matullo et al., 2006 [27] Caucasian 116/1094 Population 1.10
(0.59–1.94)
9.70
(0.69–
134.6)
Replication
(random samples)
Yin et al., 2007 [47] Asian 241/249 Hospital 0.89
(0.60–1.32)
1.09
(0.54–2.18) None
Pachouri et al., 2007 [49]‡ Asian 103/122 Population 0.97
(0.54–1.76)
1.36
(0.67–2.75) None
De Ruyck et al., 2007 [30] Caucasian 110/110 Hospital 0.43
(0.15–1.12) —N o n e
Chang et al., 2009 [33] Latino 112/296 Population 0.73
(0.37–1.49) — Replication
(random samples)
Chang et al., 2009 [33] African-
American 254/280 Population 1.23
(0.64–2.30) — Replication
(random samples)
Summary∗∗ No. of
populations
Cochran Q test for
heterogeneity
Arg/Trp Trp/Trp
All 13 4,431/6,320
0.89
(0.79–
1.00)†
1.15
(0.80–1.67) 0.467 0.510
Caucasian (mostly composed
of Caucasians) 6 3,335/4,824 0.89
(0.77–1.03)
1.24
(0.50–3.11) 0.653 0.315
Asian 4 576/686 0.93
(0.72–1.20)
1.18
(0.72–1.93) 0.476 0.305
∗Crude odds ratio and 95% conﬁdence interval.
∗∗Based on random eﬀects model.
†P = .047.
‡Excluded from the meta-analysis because genotype distribution of control population was not in Hardy-Weinberg equilibrium.
signiﬁcance (P = .004). Both the Egger’s and Begg’s tests
were not statistically signiﬁcant, however. The summary
ORs for the 339Gln/Gln genotype among Caucasians and
Asians were 0.95 (95% CI = 0.83–1.10) and 1.08 (95% CI
= 0.78–1.49), respectively. Evidence for publication bias was
absent in subgroup analyses by ethnic. The Cochran Q test
for heterogeneity showed a statistical signiﬁcance among
Asians.
A further analysis on histological type (adenocarcinoma
and squamous cell carcinoma) was carried out. Although
available data were not suﬃcient, there were no statistically
signiﬁcant diﬀerences in risk associated with the XRCC1
Arg399Gln polymorphism and adenocarcinoma or squa-
mouscellbothCaucasiansandAsians[25,38,42,44,45,49].
Table 4 shows summary ORs of the XRCC1 Arg194Trp
polymorphism [25–27, 30, 33–35, 37, 45–47, 49]. One studyJournal of Nucleic Acids 7
Table 5: Genetic polymorphisms in the BER pathway and lung cancer risk: XRCC1 Arg280His polymorphism.
Author, published year
(reference no.) Ethnicity
No. of
Cases/
controls
Source of
controls
OR (95% CI)∗ Quality control of genotyping
Arg/His Arg/His or
His/His
Ratnasinghe et al., 2001 [34] Asian 106/209 Population 1.40
(0.70–2.60)
1.60
(0.90–2.90) Replication (random sample)
Mirsa et al., 2003 [39] Caucasian 309/302 Population 1.12
(0.70–1.80)
1.17
(0.73–1.87) Replication (random samples)
Hung et al., 2005 [25]
Mostly
composed of
Caucasians
2,088/2,092 Hospital 0.95
(0.77–1.18)
0.95
(0.77–1.17) Replication (random samples)
Vogel et al., 2004 [23] Caucasian 256/269 Population 0.98
(0.53–1.79)
1.01
(0.56–1.85) Replication (random samples)
Schneider et al., 2005 [45] Caucasian 446/622 Hospital 0.93
(0.59–1.44)
0.97
(0.63–1.53) None
Shen et al., 2005 [46] Asian 111/110 Population 1.14
(0.60–2.18)
1.29
(0.69–2.41) None
Zienolddiny et al., 2006 [26]‡ Caucasian 324/377 Population 1.53
(0.85–2.78)
1.45
(0.82–2.56) Replication (All samples)
Yin et al., 2007 [47] Asian 238/242 Hospital 0.73
(0.46–1.16)
0.72
(0.46–1.12) None
De Ruyck et al., 2007 [30] Caucasian 110/110 Hospital 0.26
(0.06–0.87)
0.26
(0.06–0.87) None
Chang et al., 2009 [33] Latino 112/296 Population 1.11
(0.53–2.20)
1.08
(0.53–2.10) Replication (random samples)
Chang et al., 2009 [33] African-
American 254/280 Population — — Replication (random samples)
Summary∗∗ No. of
populations
Cochran Q test for
heterogeneity
Arg/His Arg/His or His/His
All 10 4,030/4,532 0.96
(0.83–1.11)
0.99
(0.83–1.19) 0.525 0.281
Caucasian (mostly composed
of Caucasians) 5 3,209/3,395 0.95
(0.80–1.13)
0.96
(0.80–1.17) 0.400 0.357
Asian 3 455/561 0.99
(0.66–1.48)
1.10
(0.66–1.84) 0.236 0.076
∗Crude odds ratio and 95% conﬁdence interval.
∗∗Based on random eﬀects model.
‡Excluded from the meta-analysis because genotype distribution of control population was not in Hardy-Weinberg equilibrium.
[49] was excluded from the meta-analysis because allelic
frequency in control population is not in HWE. Based on
11 studies in 13 diﬀerent ethnic populations on the basis
of 4,431 cases and 6,320 controls, the summary ORs for the
Arg/Trp genotype and Trp/Trp genotype were 0.89 (95% CI
= 0.79–1.00, P = .047) and 1.15 (95% CI = 0.80–1.67),
respectively. The ORs for the Trp/Trp genotype were 1.24
(95% CI = 0.50–3.11) in Caucasians and 1.18 (95% CI =
0.72–1.93) in Asians. This polymorphism was not associated
with lung cancer risk among both Caucasians and Asians.
Evidence for heterogeneity and publication bias was absent
in any analysis.
Table 5 shows summary ORs of the XRCC1 Arg280His
polymorphism [23, 25, 26, 30, 33, 34, 39, 45–47]. One
study [26] was excluded from the meta-analysis because
genotype distribution in control population does not fulﬁll
HWE. The summary OR for the Arg/His versus the Arg/Arg
genotype among 9 studies on the basis of 4,030 cases and
4,532 controls was 0.96 (95% CI = 0.83–1.11). The summary
OR for the Arg/His and His/His genotypes combined versus
the Arg/Arg genotype was 0.99 (95% CI = 0.83–1.19).
The summary ORs for the Arg/His and His/His genotypes
combined versus the Arg/Arg genotype in Caucasians and
Asians were 0.96 (95% CI = 0.80–1.17) and 1.10 (95% CI
= 0.66–1.84), respectively. There was no ethnic diﬀerence
in the association between lung cancer risk and the XRCC1
Arg280His polymorphism. Evidence for heterogeneity and
publication bias was absent in subgroup analyses by ethnic.
3.3. XPA G23A Polymorphism. Table 6 shows summary ORs
of the XPA G23A polymorphism on the basis of 2,025 cases
and 1,991 controls [26, 30, 42, 50–52]. SNP alleles with
higher frequencies are more likely to be ancestral than less
frequently occurring alleles although there may be some8 Journal of Nucleic Acids
Table 6: Genetic polymorphisms in the NER pathway and lung cancer risk: XPA G23A polymorphism.
Author, published year
(reference no.) Ethnicity No. of Cases
/controls
Source of
controls
OR (95% CI)∗ Quality control of
genotyping
G/A G/G
Park et al., 2002 [50] Asian 265/185 Population 1.00
(0.62–1.62)
0.62
(0.35–1.10) Sequencing
Wu et al., 2003 [51] Caucasian 564/581 Population 0.65
(0.48–0.87)
0.74
(0.55–1.01) None
Wu et al., 2003 [51] Mexican-
American 50/47 Population 0.31
(0.09–1.00)
0.40
(0.13–1.25) None
Wu et al., 2003 [51] African-
American 71/67 Population 0.54
(0.16–1.68)
0.49
(0.15–1.49) None
Popanda et al., 2004 [42] Caucasian 461/457 Hospital 0.77
(0.48–1.21)
0.82
(0.52–1.30)
Replication
(random samples)
Vogel et al., 2005 [52] Caucasian 256/269 Population 0.78
(0.41–1.49)
0.57
(0.30–1.06) None
Zienolddiny et al., 2006 [26] Caucasian 248/276 Population 0.87
(0.48–1.57)
1.41
(0.79–2.52)
Replication (all
samples)
De Ruyck et al., 2007 [30] Caucasian 110/109 Hospital 1.00
(0.34–2.92)
1.02
(0.34–3.03) None
Summary∗∗ No. of
populations
Cochran Q test for
heterogeneity
G/A G/G
All 8 2,025/1,991 0.74
(0.61–0.90)
0.76
(0.61–0.94) 0.640 0.345
Caucasian 5 1,639/1,692 0.73
(0.59–0.90)
0.83
(0.64–1.08) 0.855 0.266
∗Crude odds ratio and 95% conﬁdence interval.
∗∗ Based on random eﬀects model.
exceptions. As the 23G allele was more prevalent than the
23A allele [53], we regarded the 23G allele as ancestral (wild-
type or major) allele for descriptive purposes (the XPA 23
polymorphism caused by the G-to-A substitution is the XPA
G23A polymorphism). Summary ORs for the G/A genotype
and G/G genotype among 6 studies in 8 populations were
0.74 (95% CI = 0.61–0.90) and 0.76 (95% CI = 0.61–
0.94), respectively (Table 6, Figure 1). Among Caucasian
studies, the summary ORs for the G/A genotype and the
A/A genotype were 0.73 (95% CI = 0.59–0.90) and 0.83
(95% CI = 0.64–1.08), respectively. The Cochran Q test for
heterogeneity did not show a statistical signiﬁcance. The
Egger’s test was statistically signiﬁcant for publication bias in
as u b g r o u pa n a l y s i so fC a u c a s i a n s( P = .024, G/A genotype
versus G/G genotype).
3.4. ERCC2/XPD Polymorphism. Table 7 shows summary
ORs of the ERCC2 Asp312Asn polymorphism on the basis
of 6,346 cases and 7,792 controls [26, 27, 30, 39, 42, 48, 54–
63]. The summary OR for the Asn/Asn genotype among
17 diﬀerent ethnic populations was 1.19 (95% CI = 1.03–
1.38). Caucasians with the Asn/Asn genotype and Asian with
the Asn/Asn genotype had a marginal 1.15-fold (95% CI
= 0.98–1.32, P = .079) and a signiﬁcant 8.26-fold (95%
CI = 1.50–45.6, P = .015) risk of developing lung cancer,
respectively. No signiﬁcant association between lung cancer
and the heterozygous Asp/Asn genotype was found for
all of the studies combined or by ethnicity. The impact
of the heterozygous genotype on lung cancer was similar
between Caucasians and Asians. The Cochran Q test for
heterogeneity did not show a statistical signiﬁcance in all
analyses.Althoughnoevidenceofpublicationbiaswasfound
in overall analyses, both Begg’s (P = .040) and Egger’s (P =
.010) tests showed a statistical signiﬁcance in a subgroup
analysis of Caucasians (Asn/Asn genotype versus Asp/Asp
genotype).
Table 8 shows summary ORs of the ERCC2 Lys751Gln
polymorphism [26, 27, 30, 37, 39, 42, 43, 48, 55–65]. One
study [26] was excluded from the meta-analysis because
genotype distribution in control population signiﬁcantly
deviates from HWE. Based on 6,941 cases and 8,595
controls, summary ORs for the Gln/Gln genotype and
Lys/Gln genotype were 1.09 (95% CI = 1.04–1.18) and 1.27
(95% CI = 1.10–1.46), respectively. The Gln/Gln genotype
was signiﬁcantly associated with an increased risk of lung
cancer in Caucasians (OR = 1.24, 95% CI = 1.06–
1.45) (Figure 2) but not in Asians (OR = 1.16, 95%
CI = 0.48–2.80). The Cochran Q test for heterogeneity
showed a statistical signiﬁcance among Asian studies. Evi-
dence of publication bias was absent in all of the analy-
ses.Journal of Nucleic Acids 9
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Figure 1: Meta-analysis of 8 studies (5 Caucasian studies and 3 non-Caucasian studies) of lung cancer and theXPA G23A polymorphism
(GG versus AA). The center of a box and the horizontal line (logarithm) indicate the odds ratio (OR) and the 95% conﬁdence interval
(CI) in each study, with the areas of the boxes representing the weight of each study. The summary OR based on random eﬀects model is
represented by the middle of a diamond whose width indicated the 95% CI. The summary OR is shown by the dotted vertical line. Statistical
heterogeneity between studies was assessed with Cochran Q test (Q = 7.86, P = .35). Summary: OR = 0.76 (95% CI = 0.61–0.94).
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Figure 2: Meta-analysis of 10 Caucasian studies of lung cancer and the ERCC2 Lys751Gln polymorphism (Gln/Gln versus Lys/Lys). The
center of a box and the horizontal line (logarithm) indicate the odds ratio (OR) and the 95% conﬁdence interval (CI) in each study, with the
areas of the boxes representing the weight of each study. The summary OR based on random eﬀects model is represented by the middle of a
diamond whose width indicated the 95% CI. The summary OR is shown by the dotted vertical line. Statistical heterogeneity between studies
was assessed with Cochran Q test(Q = 2.75, P = .97). Summary: OR = 1.24 (95% CI = 1.06–1.45).
4. Discussion
EpidemiologicalstudiesofcommonpolymorphismsinDNA
repair genes, if large and unbiased, can provide insight
into the in vivo relationships between DNA repair genes
and lung cancer risk. Such studies may identify empirical
associations which indicate that a polymorphism in a gene
of interest has an impact on lung cancer, independent of
metabolic regulatory mechanisms and other genetic and
environmental variability. Findings from epidemiological
studies can complement in vitro analyses of the various
polymorphisms, genes, and pathways. In addition, epidemi-
ological studies of common polymorphisms can lead to an
increased understanding of the public health dimension of
DNA-repair variation.
We conducted a systematic literature review to evaluate
the associations between sequence variants in DNA repair
genes and lung cancer risk. We found an increased risk of
lungcanceramongsubjectscarryingtheERCC2751Gln/Gln
genotype in Caucasians (OR = 1.24, 95% CI = 1.06–1.45).
The meta-analysis by Hu et al., showed that the Gln/Gln
genotype had a signiﬁcant 23% (95% CI = 3%–47%)
increased risk of lung cancer compared with individuals
with the Lys/Lys genotype among Caucasians [66]. The
meta-analysis by Benhamou and Sarasin reported that the
summary OR for the Gln/Gln genotype was 1.25 (95% CI =
1.03–1.52) in the United States (stratiﬁed by geographic
region) [67]. Both of the meta-analyses were based on the
same published data from 8 individual case-control (ﬁve
Caucasian and three Asians) studies [37, 39, 55–58, 64, 65].10 Journal of Nucleic Acids
Table 7: Genetic polymorphisms in the NER pathway and lung cancer risk: ERCC2 Asp312Asn polymorphism.
Author, published year
(reference no.) Ethnicity No. of
Cases/controls
Source of
controls
OR (95% CI)∗ Quality control of
genotyping
Asp/Asn Asn/Asn
Butkiewicz et al., 2001 [54] Caucasian 96/94 Population 0.49
(0.24–0.98)
0.71
(0.29–1.74) Sequencing
Spitz et al., 2001 [55] Admixed
population 195/257 Population 0.92
(0.62–1.36)
1.54
(0.78–3.05) None
Hou et al., 2002 [56] Caucasian 184/162 Population 1.27
(0.78–2.05)
0.88
(0.43–1.84)
Replication
(random samples)
Zhou et al., 2002 [57] Caucasian 1,092/1,240 Population 0.98
(0.82–1.17)
1.41
(1.06–1.86)
Replication
(random samples)
Liang et al., 2003 [58] Asian 1,006/1,020 Population 0.98
(0.76–1.28)
11.2
(1.45–87.2)
Replication
(random samples)
Misra et al., 2003 [39] Caucasian 313/312 Population 0.76
(0.53–1.07)
0.94
(0.56–1.59)
Replication
(random samples)
Popanda et al., 2004 [42] Caucasian 463/460 Hospital 1.14
(0.77–1.68)
1.03
(0.70–1.51)
Replication
(random samples)
Vogel et al., 2004 [59] Caucasian 252/263 Population 1.27
(0.86–1.89)
1.09
(0.63–1.86) None
Shen et al., 2005 [60] Asian 118/113 Population 0.58
(0.21–1.52) — Replication
(random samples)
Zienolddiny et al., 2006 [26] Caucasian 275/290 Population 0.85
(0.58–1.25)
1.11
(0.68–1.81)
Replication (all
samples)
Matullo et al., 2006 [27] Caucasian 116/1094 Population 0.81
(0.52– 1.26)
0.95
(0.51–1.71)
Replication
(random samples)
Hu et al., 2006 [61] Asian 970/986 Hospital 1.07
(0.81–1.43)
4.11
(0.41–
202.7)
None
L´ opez-Cima et al., 2007 [48] Caucasian 516/533 Hospital 1.04
(0.80–1.35)
1.39
(0.88–2.20) Sequencing
De Ruyck et al., 2007 [30] Caucasian 110/109 Hospital 1.28
(0.70–2.35)
1.03
(0.40–2.66) None
Chang et al.,2008 [62] Latino 108/297 Population 1.37
(0.83–2.26)
2.13
(0.72–5.96)
Replication
(random samples)
Chang et al.,2008 [62] African-
American 247/277 Population 1.10
(0.71–1.70)
0.68
(0.10–3.57)
Replication
(random samples)
Yin et al., 2009 [63] Asian 285/285 Hospital 1.31
(0.77–2.77) — Replication
(random samples)
Summary∗∗ No. of
populations
Cochran Q test for
heterogeneity
Asp/Asn Asn/Asn
All 17 (15) 6,346/7,792 1.00
(0.92–1.10)
1.19
(1.03–1.38) 0.510 0.510
Caucasian 10 3,417/4,557 0.98
(0.86–1.11)
1.15
(0.98–1.34) 0.257 0.770
Asian 4 (2) 2,379/2,404 1.02
(0.85–1.22)
8.26
(1.50–45.6) 0.565 0.597
∗ Crude odds ratio and 95% conﬁdence interval.
∗∗ Based on random eﬀects model.
These meta-analyses also indicate that the excess lung cancer
risk from the Gln/Gln genotype may be about 20%. The Gln
allele of the ERCC2 Lys751Gln polymorphism is associated
with a higher DNA adduct level or lower DNA repair eﬃ-
ciency [56, 68, 69], except in research published by Duell et
al.,whofoundnocorrelationbetweentheERCC2Lys751Gln
polymorphism and the level of polyphenol-DNA adducts in
human blood samples [70]. Thus, it is biologically plausible
that subjects with the Gln/Gln genotype are at increased risk
of lung cancer. As with the two meta-analyses, in our meta-
analysis the Gln/Gln genotype was not associated with an
increased risk of lung cancer among Asians. The CochranJournal of Nucleic Acids 11
Table 8: Genetic polymorphisms in the NER pathway and lung cancer risk: ERCC2 Lys751Gln polymorphism.
Author, published year
(reference no.) Ethnicity No. of
Cases/controls
Source of
controls
OR (95% CI)∗∗ Quality control of
genotyping
Lys/Gln Gln/Gln
David-Beabes et al., 2001 [64] Caucasian 178/453 Population 1.14
(0.77–1.71)
1.72
(1.00–2.94)
Replication
(random samples)
David-Beabes et al., 2001 [64] African-
American 153/234 Population 1.14
(0.73–1.78)
1.39
(0.54–3.55)
Replication
(random samples)
Spitz et al., 2001 [55] Admixed
population 341/360 Population 1.07
(0.78–1.46)
1.36
(0.84–2.20) None
Chen et al., 2002 [37] Asian 109/109 Population 0.79
(0.17–1.11)
0.44
(0.17–1.11) None
Hou et al., 2002 [56] Caucasian 185/162 Population 1.22
(0.75–2.00)
1.11
(0.58–2.13)
Replication
(random samples)
Zhou et al., 2002 [57] Caucasian 1,092/1,240 Population 1.01
(0.84–1.21)
1.17
(0.90–1.51)
Replication
(random samples)
Park et al., 2002 [65] Asian 250/163 Population 1.06
(0.55–2.11) —N o n e
Liang et al., 2003 [58] Asian 1,006/1,020 Population 0.93
(0.73–1.18)
2.36
(0.90–6.17)
Replication
(random samples)
Misra et al., 2003 [39] Caucasian 310/302 Population 0.87
(0.60–1.26)
1.06
(0.64–1.76)
Replication
(random samples)
Popanda et al., 2004 [42] Caucasian 463/459 Hospital 1.14
(0.86–1.52)
1.37
(0.93–2.02)
Replication
(random samples)
Harms et al., 2004 [43] Caucasian 110/119 Population 1.34
(0.79–2.49)
1.07
(0.34–3.38)
Replication (all
samples)
Vogel et al., 2004 [59] Caucasian 256/269 Population 1.57
(1.05–2.34)
1.73
(1.01–2.96) None
Shen et al., 2005 [60] Asian 118/108 Population 0.44
(0.18–1.03) — Replication
(random samples)
Zienolddiny et al., 2006 [26]‡ Caucasian 317/386 Population 1.20
(0.84–1.73)
1.56
(1.06–2.31)
Replication (all
samples)
Matullo et al., 2006 [27] Caucasian 116/1094 Population 1.23
(0.78–1.96)
1.17
(0.63–2.11)
Replication
(random samples)
Hu et al., 2006 [61] Asian 975/997 Hospital 1.16
(0.89–1.52)
1.46
(0.40–5.87) None
De Ruyck et al., 2007 [30] Caucasian 110/109 Hospital 1.07
(0.58–1.97)
1.46
(0.55–3.94) None
L´ opez-Cima et al., 2007 [48] Caucasian 516/533 Hospital 1.08
(0.83–1.41)
1.25
(0.80–1.95) Sequencing
Chang et al.,2008 [62] Latino 113/299 Population 1.01
(0.61–1.66)
2.89
(1.20–6.91)
Replication
(random samples)
Chang et al., 2008 [62] African
American 255/280 Population 1.20
(0.83–1.74)
1.01
(0.41–2.43)
Replication
(random samples)
Yin et al., 2009 [63] Asian 285/285 Hospital 1.68
(1.06–2.67)
1.47
(0.24–10.1)
Replication
(random samples)
Summary∗∗ No. of
populations
Cochran Q test for
heterogeneity
Lys/Gln Gln/Gln
All 20 (18) 6,941/8,595 1.09
(1.04–1.18)
1.27
(1.10–1.46) 0.613 0.727
Caucasian 10 3,336/4,740 1.10
0.99–1.22)†
1.24
(1.06–1.45) 0.702 0.973
Asian 6 (4) 2,743/2,682 1.04
(0.81–1.35)
1.16
(0.48–2.80) 0.085 0.096
∗ Crude odds ratio and 95% conﬁdence interval. ∗∗ Based on random eﬀects model. †P = .051
‡ Excluded from the meta-analysis because genotype distribution of control population was not in Hardy-Weinberg equilibrium.12 Journal of Nucleic Acids
Q test for heterogeneity showed a statistical signiﬁcance
among Asian studies. The presence of heterogeneity may
compromisetheinterpretationofmeta-analysesandresultin
erroneous and potentially misleading conclusions [71, 72].
The presence of signiﬁcant heterogeneity suggests that the
estimated OR in each study is not homogeneous and the
estimated ORs are close to 1.0 in the larger studies. Pos-
sible sources of heterogeneity are ethnicity (the prevalence
of the “at risk” allele, ethnic diﬀerences in roles of the
polymorphism), study design, and so on. Another possible
reason for heterogeneity is linkage disequilibrium, with
additional allelic variants of this gene that modulate overall
enzyme activity. Furthermore, it is possible that interaction
with polymorphisms at other genes may be important.
Heterogeneity can be taken into account by applying the
random eﬀects model, however. This discrepancy between
Caucasian studies and Asian studies may only be due to a
diﬀerence in sample sizes. Reasons for this diﬀerence in risk
among diﬀerent ethnic populations are as yet unknown but,
if real, may be related to other genetic or environmental
factors.
In contrast to the Lys751Gln polymorphism, the
Asp312Asn polymorphism was not associated with an
increased risk of lung cancer among Caucasians. Both Begg’s
and Egger’s tests were statistically signiﬁcant for publication
bias in a subgroup analysis of Caucasians. Publication bias
may be always a possible limitation of combining data
from various sources as in a meta-analysis. The idea of
adjusting the results of meta-analyses for publication bias
and imputing “ﬁctional” studies into a meta-analysis is
controversial at the moment [73]. Although publication
bias is always a possible limitation of combining data
from various sources as in a meta-analysis, Sutton et al.,
concludedthatpublicationorrelatedbiasesdidnotaﬀectthe
conclusions in most meta-analyses because missing studies
changed the conclusions in less than 10% of meta-analyses
[73]. Two meta-analyses have been published in 2004 [66]
and 2005 [67], respectively. Both of them are based on the
same published data from 6 individual case-control (ﬁve
Caucasian and one Asian) studies [54–58, 74]. The ﬁrst
meta-analysis showed that individuals with the Asn/Asn
genotype were associated with an increased risk of lung
cancer among Caucasians (OR = 1.22, 95% CI = 0.99–
1.49). The second meta-analysis was somewhat diﬀerent
fromtheﬁrstone,becauseunadjustedORsweresummarized
in the ﬁrst one. A signiﬁcantly increased risk of lung
cancer associated with the Asn/Asn genotype of the ERCC2
Asp312Asn polymorphism in the United States was found
(OR = 1.43, 95% CI = 1.11–1.83) [67]. The study of Zhou et
al.,[57],whichwasbasedonalargesamplesizeandobserved
the signiﬁcant result (OR = 1.5, 95 % CI = 1.1–2.0), made
a signiﬁcant inﬂuence on the summary OR of the United
States. In this study, a signiﬁcant 8.26-fold (95% CI = 1.50–
45.6) risk of developing lung cancer was observed among
Asians. This ﬁnding was entirely due to the study of Liang
et al. [58]. Although no clear association between ERCC2
Asp312Asn polymorphism and lung cancer can be found,
the Asn allele of the ERCC2 Asp312Asn polymorphism has
been reported to be associated with a higher DNA adduct
level or lower DNA repair eﬃciency [56]. Therefore, it is
plausible that the Asn allele is associated with an increased
risk of lung cancer. The Lys751Gln polymorphism has been
more studied than the Asp312Asn polymorphism because
the frequency of the 751Gln allele is more prevalent than the
312Asn allele. Moreover, the Asp312Asn polymorphism is
in linkage disequilibrium with the Lys751Gln polymorphism
[54, 55, 58]. As absence of association with lung cancer risk
and Asp312Asn polymorphism may be partly due to the low
prevalence of the 312Asn allele (low statistical power), the
ﬁnding on the ERCC2 Asp312Asn polymorphism should be
interpreted with caution before being conﬁrmed in future
studies.
Incontrast,wefoundaprotectiveeﬀectoftheXPGG23A
G/G genotype (OR = 0.76, 95% CI = 0.61–0.94) on lung
cancer risk. The XPA G23A polymorphism itself may alter
the transcription and/or translation of the gene. Because this
polymorphism is located in the vicinity of the translation
initiation codon, it may alter translation eﬃciency. The
nearby proximal nucleotides to the AUG initiation codon
are important for the initiation of translation because the
40S ribosomal subunit binds initially at the 5 -end of the
mRNA [75]. The consensus sequence around the start
codon is GCCRCCAUGG, which is known as the Kozak
consensus sequence [76]. The R at position −3 and the G
just downstream of the start codon are especially important,
and the lack of these bases leads to read-through of the start
codon [77]. However, there has been no precise explanation
of the mechanism by which the recognition of the start
codon is aided by a purine at position −3[ 76], which is the
core nucleotide of the Kozak consensus. The polymorphism
XPA G23A is a G/A transversion occurring four nucleotides
upstream of the start codon of XPA and possibly improving
the Kozak sequence [50]. The sequences (CCAGAGAUGG)
around the predicted initiator methionine codon of the XPA
gene agree with the Kozak’s consensus sequence at positions
−3 and +4 [78]. Although both the A and polymorphic
variant G nucleotides at the −4 position of the XPA gene
do not correspond to the original consensus Kozak sequence
containing the nucleotide C at position −4, it is possible
that a nucleotide substitution of A to G at position-4
preceding the AUG codon may aﬀect ribosomal binding
and thus alter the eﬃciency of XPA protein synthesis. To
investigate whether the transition from G to A changes the
translation eﬃciency, an in vitro transcription/translation
analysis and a primer extension assay of the initiation
complex will be necessary in the future. Furthermore, a
functionalassociation betweentheG23Apolymorphism and
DRC was reported [51], which showed signiﬁcantly higher
repair eﬃciency in healthy subjects with at least one G allele.
An alternative explanation could be that the protective XPA
23G allele is in linkage disequilibrium with an allele from
an adjacent gene which is the true susceptibility gene. The
XPA G23A polymorphism may be a promising SNP for
lung cancer. It is thought that cigarette smoking modiﬁes
the association between DNA repair polymorphisms, as well
as metabolic polymorphisms, and lung cancer risk. Since
interactions between the XPA G23A polymorphism and
smoking have not been fully elucidated, further studies areJournal of Nucleic Acids 13
needed to better understand the associations between the
XPA G23A polymorphism and lung cancer risk.
The Cys/Cys genotype of the OGG1 Ser326Cys poly-
morphism was signiﬁcantly associated with lung cancer risk
in all of the studies combined (OR = 1.22, 95% CI =
1.02–1.45) and was marginally associated with lung cancer
risk in Asian populations (OR = 1.24, 95% CI = 1.00–
1.55, P = .052). In the stratiﬁed analysis by histological
type of lung cancer, a signiﬁcant association was found
for adenocarcinoma. In a narrative review, the Ser326Cys
polymorphism has inconsistently been associated with risk
of lung cancer [79]. There was an increased risk of lung
canceramong subjectswiththe OGG1326Cys/Cys genotype,
which is consistent with experimental evidence that this
isoform exhibits decreased the BER activity [80, 81]. The
meta-analysis of Hung et al. showed that the summary OR
was 1.37 (95% CI = 1.02–1.82) for the Cys/Cys genotype
in various ethnic populations combined [82]. The meta-
analysis of Li et al. showed that individuals carrying the
Cys/Cys genotype did not have signiﬁcantly increased risk of
lung cancer in all populations combined but, in the stratiﬁed
analysis by ethnicity, a signiﬁcantly increased risk was found
among Asians (OR = 1.18, 95% CI = 1.01–1.38) [83].
Ethnic diﬀerence in the association between lung cancer
risk and the OGG1 Ser326Cys polymorphism was suggested.
Large studies including diﬀerent ethnic groups with a careful
matchingbetweencasesandcontrolsshouldbeconsideredin
future association studies to conﬁrm results from the meta-
analyses.
None of the XRCC1 polymorphisms was associated with
an increased risk of lung cancer among both Caucasians and
Asians. Our result for the XRCC1 Arg280His and Arg399Gln
polymorphisms replicated the results of the meta-analysis by
Hung et al. [82]. Results of previous studies that examined
theassociationbetweentheXRCC1polymorphismsandlung
cancer risk were inconsistent, possibly owing to the large
random error in several small studies. This inconsistency
might be due, in part, to diﬀerences in the prevalence of
smokers. Lunn et al., [84]m e a s u r e dh i g h e rl e v e l so fa ﬂ a t o x i n
B1 adducts in the XRCC1 Arg399Gln polymorphism and
suggested that this might result in a deﬁcient DRC. Two
other XRCC1 polymorphisms, Arg194Trp and Arg280His,
have been also determined and the functional eﬀect of these
polymorphisms is also unclear, even though some studies
have revealed that amino acid changes at the evolutionary
conserved regions can alter its function [85]. Although
these polymorphisms result in amino acid substitutions,
there is no direct evidence on its functional consequences.
The XRCC1 Arg399Gln polymorphism has been associated
with risk of breast cancer among African Americans, but
not among Caucasians [86, 87], indicating that the XRCC1
Arg399Gln polymorphism may be linked to another bio-
logically eﬀective mutation. Further investigations of the
combinedeﬀectsofpolymorphismswithintheseDNArepair
genes, smoking, and other risk factors may help to clarify the
inﬂuence of genetic variation in the carcinogenic process.
Several DNA repair pathways are involved in the mainte-
nance of genetic stability. The most versatile and important
one is the NER pathway, which detects and removes bulky
DNA adducts, including those induced by cigarette smoking
[88]. However, there are several conﬂicting reports on the
association between this polymorphism and lung cancer
risk among various populations. Although the reasons for
the inconsistencies in the studies are not clear, possible
explanations are (1) low frequency of the “at-risk” genotype,
which would reduce the statistical power of the studies and
(2) small size of the studies. Ethnic diﬀerences in the roles of
the polymorphism may be caused by gene-gene interactions,
diﬀerent linkages to the polymorphisms determining lung
cancer risk, and diﬀerent lifestyles.
The most important problems facing lung cancer
research are identifying “at-risk” individuals and imple-
menting clinical surveillance, prevention practices, and
follow-up care. Repair pathways play an important role in
lung cancer risk, and genetic variations may contribute to
decreased DRC and lung cancer susceptibility. Although
the increased/decreased risk associated with individual DNA
repair SNPs may be small compared to that conferred by
high-penetrance cancer genes, their public health implica-
tion may be large because of their high frequency in the
general population. It is thus essential that epidemiological
investigations of DNA repair polymorphisms are adequately
designed. Unfortunately a fairly good number of studies are
limited by their sample size and subsequently suﬀer from too
low power to detect eﬀects that may truly exist. Also, given
theborderline signiﬁcanceofsomeassociationsandmultiple
comparisons that have been carried out, there is a possibility
that one or more ﬁndings are false-positives [89]. Large
and combined analyses may be preferred to minimize the
likelihood of both false-positive and false-negative results.
In addition, controls should be chosen in such a way that,
if they were cases, they would be included in the case
group; when controls are matched to cases, it is essential
to account for matching in the analysis. When appropriate,
confounding factorsshould be controlledfor,withparticular
consideration of race and ethnicity. An additional major
concern is the grouping of genotypes for calculation of
ORs. Without functional data to dictate genotype groupings,
it seems prudent to present two ORs per polymorphism
(one for heterozygotes versus common-allele homozygotes
and one for rare-allele homozygotes versus common-allele
homozygotes) so that dominant, codominant, or recessive
patterns may be elucidated.
Continued advances in SNP maps and in high-
throughput genotyping methods will facilitate the analysis
of multiple polymorphisms within genes and the anal-
ysis of multiple genes within pathways. The eﬀects of
polymorphisms are best represented by their haplotypes.
Data from multiple polymorphisms within a gene can be
combined to create haplotypes, the set of multiple alleles
on a single chromosome. None of the studies reviewed here
reported haplotype associations, although several studies
analyzed multiple polymorphisms within a gene, sometimes
with inconsistent results. The analysis of haplotypes can
increase the power to detect disease associations because
of higher heterozygosity and tighter linkage disequilibrium
with disease-causing mutations. In addition, haplotype
analysis oﬀers the advantage of not assuming that any14 Journal of Nucleic Acids
of the genotyped polymorphisms is functional; rather, it
allows for the possibility of an ungenotyped functional
variant to be in linkage disequilibrium with the genotyped
polymorphisms[90].Ananalysisofdatafrommultiplegenes
within the same DNA-repair pathway (particularly those
known to form complexes) can provide more comprehensive
insight into the studied associations. Such an analysis may
shedlightonthecomplexitiesofthemanypathwaysinvolved
in DNA repair and lung cancer development, providing
hypothesesforfuturefunctionalstudies.Becauseofconcerns
over inﬂated type I error rates in pathway-wide or genome-
wide association studies, methods of statistical analysis
seeking to obviate this problem are under development [91].
The ability to include haplotype information and data from
multiple genes, and to model their interactions, will provide
more powerful and more comprehensive assessments of the
DNA repair pathways.
This review, which is limited by the bias against
publication of null ﬁndings, highlights the complexities
inherent in epidemiological research and, particularly, in
molecular epidemiological research. There is evidence that
some polymorphisms in DNA repair genes play a role in
carcinogenesis, most notably the ERCC2 Lys751Gln and XPA
G23A polymorphisms. The variant allele of each of the three
polymorphisms was associated with about a 30% decrease
or increase in lung cancer risk. Although the summary
risk for developing lung cancer in individuals of each
genotype may not be large, lung cancer is such a common
malignancy that even a small increase in risk can translate
to a large number of excess lung cancer cases. Therefore,
polymorphisms,eventhosenotstronglyassociatedwithlung
cancer, should be considered as potentially important public
health issues. In addition, it is important to keep in mind
that a susceptibility factor in one population may not be
a factor in another. There are diﬀerences in the prevalence
of DNA repair polymorphisms across populations. In a
population where the prevalence of an “at-risk” genotype
in a given polymorphism is very low, the “at-risk” allele
or “at-risk” genotype may be too infrequent to assess its
associated risk. At a population level, the attributable risk
must be small simply because it is an infrequent allele.
Finally, the major burden of lung cancer in the population
probably results from the complex interaction between
many genetic and environmental factors over time. Most
environmental carcinogens ﬁrst require metabolic activation
by Phase I enzymes to their ultimate forms which then
bind to DNA, forming aromatic-DNA adducts that are
thought to be an early step in tumorigenesis. On the
other hand, these activated forms are detoxiﬁed by Phase
II enzymes. Thus, genetically determined susceptibility to
lung cancer may depend on the metabolic balance among
Phase I enzymes, Phase II enzymes, and DNA repair
enzymes [92]. Further investigations of the combined eﬀects
of polymorphisms between DNA repair genes and drug-
metabolizing genes may also help to clarify the inﬂuence
of genetic variation in the carcinogenic process. Consortia
and international collaborative studies, which may be a way
to maximize study eﬃcacy and overcome the limitations
of individual studies, are needed to help further illuminate
the complex landscape of lung cancer risk and genetic
variations.
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